AstraZeneca Resumes Patient Enrollment For Head And Neck Cancer Trials After FDA Lifts Hold

AstraZeneca will resume patient enrollment in two of its trial programs for neck and head cancers. The FDA lifted the partial hold, which occurred after a series of patients suffered from bleeding as a side effect of the treatment.